Combination therapy targets resistant breast cancer

NCT ID NCT00317720

Completed Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This trial investigates whether adding everolimus (RAD001) to trastuzumab (Herceptin) can help people with a specific type of advanced breast cancer that has stopped responding to trastuzumab alone. The study includes people with HER2-positive, PTEN-deficient metastatic breast cancer. The goal is to find the best dose of everolimus and to see if the combination can shrink tumors or stop them from growing for at least six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab (Herceptin) and everolimus (RAD001)
What this could lead to: If it works, this combination could offer a new treatment option for people with a specific type of breast cancer that has stopped responding to standard therapy.
What could go wrong: This is an early-phase trial with a small number of participants. The combination may cause significant side effects, and the benefit may not be confirmed in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma metastatic neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER NEOPLASM METASTASIS

Contacts and locations

Locations

UT MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.